Market Closed -
Other stock markets
|
After market 12:16:49 pm | |||
101.4 EUR | +2.85% | 101.3 | -0.02% |
06:00pm | Business Square only in green; Stellantis on top | AN |
03:36pm | DIASORIN : Markets hailed the Q1 beat; guidance re-affirmed |
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The company returns high margins, thereby supporting business profitability.
Weaknesses
- With an expected P/E ratio at 30.63 and 25.79 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company appears highly valued given the size of its balance sheet.
- The company is not the most generous with respect to shareholders' compensation.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+8.70% | 5.66B | B | ||
-3.58% | 12.64B | B+ | ||
-1.48% | 8.46B | B- | ||
+24.29% | 5.27B | C | ||
-4.58% | 4.49B | C | ||
-51.47% | 3.11B | D+ | ||
+16.25% | 2.87B | - | - | |
+31.40% | 2.31B | C | ||
-4.08% | 1.89B | D+ | ||
+3.02% | 1.64B | - | C |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- DIA Stock
- Ratings DiaSorin S.p.A.